Entries in AMD (6)


The Economic Costs of Age-Related Eye Disease

Image courtesy of wfsb.com

The American Journal of Managed Care published an online supplement by William J. Cardarelli, PharmD and Roderick A. Smith, MS discussing the current economic effects and costs of eye disease as it related to our aging population in the U.S. Areas covered include Open-Angle Glaucoma, Wet AMD, and Dry Eye Disease.

The authors concluded the following:

The trend of rising costs associated with visual impairment and the treatment of age-related ocular diseases in the United States is having a tremendous impact on patients’ caregivers, third-party payers, and society. These costs will almost certainly continue to increase in the coming decades as the baby boomer generation reaches old age. While new treatments for eye diseases are benefiting thousands of patients, the costs of these treatments are a major cause of concern.

Read the Article: Managed Care Implications of Age-Related Ocular Conditions


Aspirin May Increase AMD

ORSF Symposium's Dr. Barbara Klein and Dr. Ronald Klein from the University of Wisconsin School of Medicine & Public Health published a 2012 study in the Journal of the American Medical Association finding a long-term link between aspirin and AMD. The study concluded:

Among an adult cohort, aspirin use 5 years prior to observed incidence was not associated with incident early or late AMD. However, regular aspirin use 10 years prior was associated with a small but statistically significant increase in the risk of incident late and neovascular AMD.

The Study: Long-term use of aspirin and age-related macular degeneration


ORSF Symposium's Emily Chew Discusses Her New Study

Image courtesy of the US National Library of MedicineImage courtesy of shape.com








ORSF is honored to have Emily Y. Chew, MD, of the National Eye Institute (NEI) participate in our June 2013 Symposium on the Aging Eye. She recently published a study in the Journal of the American Medical Association on supplements and macular degeneration. 

Some of the findings included:

To probe whether the addition of lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids to the currently recommended supplement offers benefit, the AREDS team conducted a randomized study of 1608 participants comparing progression of macular degeneration among individuals taking the original supplement plus lutein, zeaxanthin, and omega-3 fatty acids or the original supplement plus placebo. They did not find any additional reductions in progression in the group receiving the add-on supplementation. They did, however, find that former smokers taking the original supplement (current smokers were excluded from groups receiving beta carotene) had an increased rate of lung cancer compared with those taking a revised version of the original supplement that substituted lutein and zeaxanthin for beta carotene.

JAMA conducted a Q & A with Dr. Chew about her study. Read it here.


$6.2 Million NEI Grant Given to Develop New AMD Treatments

Northwestern University is a recent grantee of a $6.2 million grant from the National Eye Institute to develop new treatments for exudative age-related macular degeneration (AMD).

According to AZoNano.com,   

Exudative AMD is the leading cause of blindness among aging Americans, and the global rate of AMD is expected to double in the next decade due to an aging population. The severe vision loss from AMD is caused by the overgrowth of blood vessels between the outer membrane of the eye and the retina. New therapeutic approaches are needed to restore eye function lost to the disease.   

Read the article: Nanomedicine Part of Major Age-Related Macular Degeneration Study


NIH-funded Study Finds Seven Genetic Risk Factors in Common Eye Disorder

The National Eye Institute issued a press release about a recent study that found seven genetic risk factors in age-related macular degeneration (AMD).

NEI Director Paul Sieving stated the following:

"This compelling analysis by the AMD Gene Consortium demonstrates the enormous value of effective collaboration. Combining data from multiple studies, this international effort provides insight into the molecular basis of AMD, which will help researchers search for causes of the disease and will inform future development of new diagnostic and treatment strategies."

Article:  Seven genetic risk factors found to be associated with common eye disorder


ORSF's Medical Director Dr. Gerald Chader at Vision Quest 2012

ORSF's Medical Director Dr. Gerald Chader spoke at Vision Quest 2012 on "Emerging Treatments for Dry Age-Related Macular Degeneration." Please click on the video above to hear his insightful speech on AMD.